Skip to main content
IRS-authorized e-file provider · not the IRS

Nonprofit · EIN 39-4648664

FOUNDATION FOR ADENOSINE RESEARCH

Tax-exempt · CHARLOTTESVLE, VA 22901

Financials

$75K$46K2025
Revenue Expenses · by fiscal year end
Financials of FOUNDATION FOR ADENOSINE RESEARCH by year, from its e-filed returns
Year endedFormRevenueExpensesNet incomeTotal assetsLiabilitiesNet assets
December 31, 2025990-EZ$75,000$45,655$29,345$29,345$0$29,345
Financial details: 990-EZ for the year ended December 31, 2025

Revenue

Contributions, gifts and grants
$75,000
Program service revenue
$0
Investment income
$0
Other revenue
$0

Expenses

Grants and similar amounts paid
$42,500
Compensation of officers, directors and key employees
$0
Salaries, compensation and benefits (total)
$0
Professional fees and payments to contractors
$3,155
Program services (functional)
$3,155

Balance sheet and other

Total assets, start of year
$0
Total assets, end of year
$29,345
Total liabilities, end of year
$0
Net assets, end of year
$29,345
Cash, savings and investments
$29,345
Gross receipts
$75,000

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990-EZ for the year ended December 31, 2025, highest compensation first.

NameTitleHours / weekCompensation
William StilleyDirector1$0
J Kermit AndersonDirector1$0
James NewmanDirector1$0
Uday GuptaPresident & Treasurer5$0
John MartinSecretary2$0

Address and contacts

Address (IRS master file)
1180 SEMINOLE TRL STE 495, CHARLOTTESVLE, VA 22901-5739
Signed the 990-EZ
Uday Gupta, President & Treasurer
Phone
(434) 226-0683
Return prepared by
Shuru Law LLC

Mission

To advance scientific understanding and innovation in the field of adenosine biology by supporting the exploration of adenosine's role in human health and disease, fostering collaboration across disciplines, and accelerating discoveries into transformative therapies for the benefit of patients and society, as well as the making of distributions to organizations that qualify as exempt organizations under the Internal Revenue Code.

990-EZ for the year ended December 31, 2025

Program accomplishments

  • Research Grantmaking and Scientific Program Support. 70 percent of total activity and 85-88 percent of expenses. FAR awards research grants and provides targeted financial support for early stage scientific investigations in adenosine biology. Grants are designed to support hypothesis-driven preclinical and translational research, including pilot studies, proof-of-concept experiments, and data generation necessary to advance understanding of adenosine signaling in areas such as oncology, autoimmune disease, inflammation, and metabolic disorders. Scientific review and funding recommendations are supported by external scientific advisors and, beginning in 2026, a formal Scientific Advisory Council composed of independent subject-matter experts who serve as unpaid volunteers. Funded research activities are conducted at third-party academic institutions, nonprofit research organizations, and qualified research laboratories in the US. FAR does not operate laboratory facilities. Activity is funded entirely through charitable donations. Expenses are allocable to research grants, pilot studies, and associated scientific program support. Activity directly furthers FAR's scientific and educational purposes by advancing basic and translational research related to adenosine biology. Funding early stage research reduces barriers to discovery, promotes dissemination of scientific knowledge, and accelerates progress toward therapies that benefit public health.
    grants $42,500
  • ACCORD (Adenosine Cancer Collaborative for Oncology Research and Discovery). 10 percent of total activity and 5-8 percent of expenses. FAR convenes and supports ACCORD, a structured scientific collaboration focused on the role of adenosine signaling in cancer biology and treatment. ACCORD facilitates coordinated data review, prioritization of research questions and alignment of preclinical research efforts across participating investigators. The activity includes invited academic researchers, clinicians and scientific advisors. ACCORD activities are conducted through virtual meetings and periodic in-person scientific convenings hosted at partner academic or research institutions. ACCORD is funded through charitable donations. Expenses are primarily for meeting coordination, scientific review support, and limited pilot study funding. By fostering collaboration and coordination among researchers, ACCORD enhances scientific efficiency, reduces duplication of effort, and promotes the generation and dissemination of new scientific knowledge related to cancer biology and treatment.
  • Scientific Advisory and Educational Convenings. 10 percent of total activity and 5-7 percent of expenses. FAR organizes scientific workshops, advisory meetings, and structured educational convenings to review emerging research, define research priorities and educate stakeholders on advances in adenosine biology. Convenings are focused on scientific exchange and strategic research planning. Activities include participation from volunteer scientific advisors, academic researchers, and clinicians. FAR's Scientific Advisory Council will participate on an unpaid, volunteer basis. Activities are conducted through virtual platforms and occasional in-person meetings hosted at academic or nonprofit venues. Funded through charitable donations. These activities further FAR's educational and scientific mission by promoting knowledge sharing, supporting informed research decision-making and advancing understanding of adenosine-related biology and disease mechanisms.
  • Governance, Compliance, and Organizational Operations. 10 percent of total activity and 5-10 percent of expenses. FAR maintains essential governance, compliance and administrative operations, including board management, financial oversight, regulatory filings, donor stewardship and organizational planning. Professional service providers (legal, accounting, insurance) are engaged as needed. Administrative activities are conducted remotely and through third-party service providers. Funded through charitable donations. Effective governance and compliance ensures FAR operates exclusively for charitable and scientific purposes and maintains accountability to donors and the public.
    Expenses $3,155

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

Tax yearYear endedDueIRS public records
2025December 31, 2025May 15, 2026990-EZ on file
2024December 31, 2024May 15, 2025Check at the IRS
2023December 31, 2023May 15, 2024Check at the IRS

File the 2026 990-EZ for FOUNDATION FOR ADENOSINE RESEARCH

Due May 17, 2027 · e-filed with the IRS by 990.tax, an IRS-authorized e-file provider

IRS record

EIN
39-4648664
Tax-exempt status
501(c)(3): Charitable, religious, educational or scientific organization
Foundation status
Publicly supported organization (170(b)(1)(A)(vi))
Donations deductible (Pub 78)
Public charity, 50% deduction limit
Exempt since
2026
Accounting year ends
December
Files
Form 990 or 990-EZ
Assets (IRS master file)
$29,345
Income (IRS master file)
$75,000

Filing history

FormYear endedRevenueExpensesAssetsReturn
990-EZDecember 2025$75,000$45,655$29,345IRS

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 39-4648664).

Questions about FOUNDATION FOR ADENOSINE RESEARCH

What is the EIN of FOUNDATION FOR ADENOSINE RESEARCH?
The employer identification number (EIN) of FOUNDATION FOR ADENOSINE RESEARCH is 39-4648664.
Is FOUNDATION FOR ADENOSINE RESEARCH tax-exempt?
Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2026.
Are donations to FOUNDATION FOR ADENOSINE RESEARCH tax-deductible?
Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
Which annual return does FOUNDATION FOR ADENOSINE RESEARCH file?
Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
When is the next return of FOUNDATION FOR ADENOSINE RESEARCH due?
The return for tax year 2026 (the year ending December 31, 2026) is due May 17, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.
When did FOUNDATION FOR ADENOSINE RESEARCH last file with the IRS?
The latest return in the IRS public files is the 990-EZ for the year ended December 2025.
Who are the officers and directors of FOUNDATION FOR ADENOSINE RESEARCH?
The 990-EZ for the year ended December 31, 2025 lists 5 people; 0 received compensation from the organization.
How much revenue does FOUNDATION FOR ADENOSINE RESEARCH have?
On its 990-EZ for the year ended December 31, 2025 it reported revenue of $75,000, expenses of $45,655 and total assets of $29,345 at year end.

Other nonprofits in CHARLOTTESVLE

All nonprofits in CHARLOTTESVLE · Virginia · Science and technology